Patents Assigned to The United States of America,as represented by the Secretary, Department of Health and Human Servic
  • Publication number: 20200085950
    Abstract: The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.
    Type: Application
    Filed: November 25, 2019
    Publication date: March 19, 2020
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Hisataka Kobayashi, Peter Choyke
  • Publication number: 20200061185
    Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
    Type: Application
    Filed: October 25, 2017
    Publication date: February 27, 2020
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, The Scripps Research Institute, Trustees of Dartmouth College
    Inventors: Barney Graham, Jason McLellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
  • Publication number: 20200054741
    Abstract: The present disclosure relates to novel peptide-based vaccines, methods of manufacturing the novel peptide-based vaccines and uses thereof for delivering peptide antigens to induce an immune response, and in particular a T cell response to a subject.
    Type: Application
    Filed: April 4, 2018
    Publication date: February 20, 2020
    Applicants: Avidea Technologies, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Geoffrey Martin Lynn, Andrew Scott Ishizuka
  • Publication number: 20200046747
    Abstract: Methods are disclosed for treating a subject with a vascular or cardiac disorder associated with oxidative stress. Methods are disclosed for treating a subject with GNE myopathy that has impaired cardiac function. These methods include administering to the subject a therapeutically effective amount of a sialic acid precursor, sialic acid, or one or more sialylated compounds, mannosamine, N-acetyl mannosamine or a derivative thereof. In other embodiments, methods are disclosed for detecting a disorder associated with oxidative stress.
    Type: Application
    Filed: October 16, 2019
    Publication date: February 13, 2020
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Marjan Huizing, May C. Malicdan, Nuria Carrillo
  • Publication number: 20200038388
    Abstract: The present invention provides a method of inhibiting release of a virus from a cell, comprising contacting the cell with a compound that binds an ubiquitin E2 variant (UEV) domain of a cellular polypeptide, or fragment thereof, with an affinity sufficient to inhibit or disrupt the binding of the cellular polypeptide, or fragment thereof, to ubiquitin.
    Type: Application
    Filed: October 30, 2017
    Publication date: February 6, 2020
    Applicants: The Research Foundation for the State University of New York, THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Carol Carter, Lorna Erlich, Nico Tjandra, Madeleine Davison
  • Publication number: 20200030261
    Abstract: This disclosure concerns the discovery of the use of fenoterol analogues for regulating cannabinoid (CB) receptor activity-related disorders and disease, such as dysregulated CB receptors, including treating a disorder or disease, such as a glioblastoma, hepatocellular carcinoma, liver cancer, colon cancer, and/or lung cancer, which is associated with altered cannabinoid receptor activity. In one example, the method includes administering to a subject having or at risk of developing a disorder or disease regulated by CB receptor activity an effective amount of a fenoterol analogue to reduce one or more symptoms associated with the disorder or disease regulated by CB receptor activity.
    Type: Application
    Filed: October 11, 2019
    Publication date: January 30, 2020
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Irving W. Wainer, Michel Bernier, Rajib K. Paul
  • Publication number: 20200009243
    Abstract: Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.
    Type: Application
    Filed: September 23, 2019
    Publication date: January 9, 2020
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, Institute for Research in Biomedicine
    Inventors: Peter Kwong, Michael Gordon Joyce, Baoshan Zhang, Yongping Yang, Peter Collins, Ursula Buchholz, Davide Corti, Antonio Lanzavecchia, Guillaume Stewart-Jones
  • Publication number: 20190374561
    Abstract: The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.
    Type: Application
    Filed: May 20, 2019
    Publication date: December 12, 2019
    Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Marjan Huizing, William A. Gahl, Irini Manoli, Enriko Klootwijk
  • Publication number: 20190370965
    Abstract: Disclosed prostate computer aided diagnosis (CAD) systems employ a Random Forest classifier to detect prostate cancer. System classify individual pixels inside the prostate as potential sites of cancer using a combination of spatial, intensity and texture features extracted from three sequences. The Random Forest training considers instance-level weighting for equal treatment of small and large cancerous lesions and small and large prostate backgrounds. Two other approaches are based on an AutoContext pipeline intended to make better use of sequence-specific patterns. Also disclosed are methods and systems for accurate automatic segmentation of the prostate in MRI. Methods can include both patch-based and holistic (image-to-image) deep learning methods for segmentation of the prostate. A patch-based convolutional network aims to refine the prostate contour given an initialization. A method for end- to-end prostate segmentation integrates holistically nested edge detection with fully convolutional networks.
    Type: Application
    Filed: February 22, 2018
    Publication date: December 5, 2019
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Nathan S. Lay, Yohannes Tsehay, Ronald M. Summers, Baris Turkbey, Matthew Greer, Ruida Cheng, Holger Roth, Matthew J. McAuliffe, Sonia Gaur, Francesca Mertan, Peter Choyke
  • Publication number: 20190314459
    Abstract: The present invention refers to a GPR101 inhibitor, antagonist or inverse agonist or inverse agonist for use in preventive and/or therapeutic treatment of diseases selected from the group consisting of acromegaly and gigantism and to methods for preventive and/or therapeutic treatment of diseases selected from the group consisting of acromegaly and gigantism. Further, the present invention provides a GPR101 agonist for use in preventive and/or therapeutic treatment of disorders selected from the group consisting of dwarfism, short stature, hypopituitarism and a disease of low levels of pituitary hormone secretion and to methods for preventive and/or therapeutic treatment of diseases selected from the group consisting of dwarfism, short stature, hypopituitarism and a disease of low levels of pituitary hormone secretion wherein to a subject GPR101 agonist is administered.
    Type: Application
    Filed: June 3, 2019
    Publication date: October 17, 2019
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, UNIVERSITE DE LIEGE, CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGE
    Inventors: Albert Beckers, Adrian Francis Daly, Fabio Rueda Faucz, Constantine A. Stratakis, Giampaolo Trivellin
  • Publication number: 20190290803
    Abstract: Methods are disclosed for fabricating a three-dimensional engineered blood retinal barrier (BRB) comprising a choroid and retinal pigment epithelial cells. The methods include the use of bioprinting. Also disclosed is a three-dimensional engineered BRB, and its use. Methods are also disclosed for using the three-dimensional engineered BRB, such as for the treatment of retinal degeneration in a subject or screening. A three-dimensional printing insert that is adapted for bioprinting on a culture substrate sheet that is securely retained within and exposed through a printing frame is also disclosed.
    Type: Application
    Filed: November 8, 2017
    Publication date: September 26, 2019
    Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary Department of Health and Human Servic
    Inventors: Kapil Bharti, Min Jae Song, Russell Louis Quinn
  • Publication number: 20190282690
    Abstract: Provided herein are recombinant respiratory syncytial viruses that contain mutations that make the disclosed viruses attractive vaccine candidates. The viruses disclosed contain attenuating mutations designed to have increased genetic and phenotypic stability. Desired combinations of these mutations can be made to achieve desired levels of attenuation. Exemplary vaccine candidates are described. Also provided are polynucleotides capable of encoding the described viruses, as wells as methods for producing the viruses and methods of use.
    Type: Application
    Filed: May 29, 2019
    Publication date: September 19, 2019
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Peter L. Collins, Cindy L. Luongo, Ursula J. Buchholz, Brian R. Murphy
  • Publication number: 20190269708
    Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.
    Type: Application
    Filed: May 15, 2019
    Publication date: September 5, 2019
    Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Walid Heneine, Thomas M. Folks, Robert Janssen, Ronald A. Otten, Jose Gerardo Garcia Lerma
  • Publication number: 20190248732
    Abstract: This disclosure concerns the discovery of (R,R)- and (R,S)-fenoterol analogues which are highly effective at binding ?2-adrenergic receptors. Exemplary chemical structures for these analogues are provided. Also provided are pharmaceutical compositions including the disclosed (R,R)-fenoterol and fenoterol analogues, and methods of using such compounds and compositions for the treatment of cardiac disorders such as congestive heart failure and pulmonary disorders such as asthma or chronic obstructive pulmonary disease.
    Type: Application
    Filed: April 22, 2019
    Publication date: August 15, 2019
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Irving William Wainer, Weizhong Zhu, Khalid Chakir, Rui-Ping Xiao, Darrell R. Abernethy, Farideh M. Beigi Abhari
  • Publication number: 20190248880
    Abstract: Monoclonal antibodies and antibody fragments that specifically bind to matrilin-3, conjugates including these molecules, and nucleic acid molecules encoding the antibodies, antigen binding fragments and conjugates, are disclosed. Also disclosed are compositions including the disclosed antibodies, antigen binding fragments, conjugates, and nucleic acid molecules. Methods of treating or inhibiting a cartilage disorder in a subject, as well as methods of increasing chondrogenesis in cartilage tissue are further provided. The methods can be used, for example, for treating or inhibiting a growth plate disorder in a subject, such as a skeletal dysplasia or short stature.
    Type: Application
    Filed: April 22, 2019
    Publication date: August 15, 2019
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Jeffrey Baron, Crystal Sao Fong Cheung, Julian Chun Kin Lui, Dimiter Dimitrov, Zhongyu Zhu
  • Publication number: 20190233885
    Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.
    Type: Application
    Filed: April 10, 2019
    Publication date: August 1, 2019
    Applicants: The Children's Medical Center Corporation, The United States of America, As Represented by the Secretary, Department of Health & Human Servic
    Inventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer
  • Publication number: 20190076457
    Abstract: A construct, or a pharmaceutically acceptable salt thereof, comprising: (a) a polyethylene glycol-block-poly(L-lysine) polymer moiety, wherein the polyethylene glycol is thiol-functionalized; (b) a cholecystokinin-B (CCK-B) receptor ligand coupled to the polyethylene glycol of the polymer moiety; and (c) a siRNA complexed with the poly(L-lysine) of the polymer moiety, wherein the construct is neutralized.
    Type: Application
    Filed: March 15, 2017
    Publication date: March 14, 2019
    Applicants: Georgetown University, The United States of America, as represented by the Secretary, Department of Health & Human Servic
    Inventors: Jill P. Smith, Stephan Stern, Abdullah Mahmud
  • Publication number: 20190055593
    Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.
    Type: Application
    Filed: October 30, 2018
    Publication date: February 21, 2019
    Applicants: The Children's Medical Center Corporation, The United States of America, As Represented by the Secretary, Department of Health & Human Servic
    Inventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer
  • Publication number: 20190048407
    Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.
    Type: Application
    Filed: October 26, 2018
    Publication date: February 14, 2019
    Applicants: The Children's Medical Center Corporation, The United States of America, As Represented by the Secretary, Department of Health & Human Servic
    Inventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer
  • Publication number: 20180291435
    Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.
    Type: Application
    Filed: June 19, 2018
    Publication date: October 11, 2018
    Applicants: The Children's Medical Center Corporation, The United States of America, As Represented by the Secretary, Department of Health & Human Servic
    Inventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer